Patents by Inventor Darién Ledesma Arroyo

Darién Ledesma Arroyo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes
    Patent number: 10919946
    Abstract: The present invention claims an isolated nucleotide sequence characterized by encoding the PFR1 protein of Leishmania infantum or a fragment thereof. This PFR1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7 and SEQ ID No: 8, where the immunodominant epitope is able to induce an antigen-specific T cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease. The immunodominant epitopes are cytotoxic T-lymphocyte activators and they present a high binding affinity for A2 type MHC Class I molecule.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: February 16, 2021
    Assignee: Consejo Superior de Investigaciones Científicas
    Inventors: Maria del Carmen Thomas Carazo, Manuel Carlos López López, Darién Ledesma Arroyo
  • CHIMERIC MOLECULE USEFUL IN IMMUNOTHERAPY FOR LEISHMANIASIS, WHICH INCLUDES A FRAGMENT OF THE PFR1 PROTEIN OF LEISHMANIA INFANTUM WITH SPECIFIC IMMUNODOMINANT EPITOPES
    Publication number: 20180312555
    Abstract: The present invention claims an isolated nucleotide sequence characterized by encoding the PFR1 protein of Leishmania infantum or a fragment thereof. This PFR1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7 and SEQ ID No: 8, where the immunodominant epitope is able to induce an antigen-specific T cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease. The immunodominant epitopes are cytotoxic T-lymphocyte activators and they present a high binding affinity for A2 type MHC Class I molecule.
    Type: Application
    Filed: February 13, 2018
    Publication date: November 1, 2018
    Inventors: Maria del Carmen THOMAS CARAZO, Manuel Carlos LÓPEZ LÓPEZ, Darién LEDESMA ARROYO
  • Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes
    Patent number: 9926349
    Abstract: The present invention claims an isolated nucleotide sequence characterized by encoding the PFR1 protein of Leishmania infantum or a fragment thereof. This PFR1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7 and SEQ ID No: 8, where the immunodominant epitope is able to induce an antigen-specific T cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease. The immunodominant epitopes are cytotoxic T-lymphocyte activators and they present a high binding affinity for A2 type MHC Class I molecule.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: March 27, 2018
    Assignee: Consejo Superior de Investigaciones Cientifícas (CSIC)
    Inventors: Maria del Carmen Thomas Carazo, Manuel Carlos López López, Darién Ledesma Arroyo
  • CHIMERIC MOLECULE USEFUL IN IMMUNOTHERAPY FOR LEISHMANIASIS, WHICH INCLUDES A FRAGMENT OF THE PFR1 PROTEIN OF LEISHMANIA INFANTUM WITH SPECIFIC IMMUNODOMINANT EPITOPES
    Publication number: 20140286974
    Abstract: The present invention claims an isolated nucleotide sequence characterized by encoding the PFR1 protein of Leishmania infantum or a fragment thereof. This PFR1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7 and SEQ ID No: 8, where the immunodominant epitope is able to induce an antigen-specific T cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease. The immunodominant epitopes are cytotoxic T-lymphocyte activators and they present a high binding affinity for A2 type MHC Class I molecule.
    Type: Application
    Filed: July 17, 2012
    Publication date: September 25, 2014
    Applicant: Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Maria del Carmen Thomas Carazo, Manuel Carlos López López, Darién Ledesma Arroyo